PDL1 is Expressed in the Islets of People with Type 1 Diabetes and is Up-regulated by Interferons-α And-γ Via IRF1 Induction

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2018 Oct 2

PMID 30269996

Citations 102

Authors

Maikel L Colli

Jessica L E Hill

Laura Marroqui

Jessica Chaffey

Reinaldo S Dos Santos

Pia Leete

Alexandra Coomans de Brachene

Flavia M M Paula

Anne Op de Beeck

Angela Castela

Lorella Marselli

Lars Krogvold

Knut Dahl-Jorgensen

Piero Marchetti

Noel G Morgan

Sarah J Richardson

Decio L Eizirik

Affiliations

Soon will be listed here.

Abstract

Background: Antibodies targeting PD-1 and its ligand PDL1 are used in cancer immunotherapy but may lead to autoimmune diseases, including type 1 diabetes (T1D). It remains unclear whether PDL1 is expressed in pancreatic islets of people with T1D and how is it regulated.

Methods: The expression of PDL1, IRF1, insulin and glucagon was evaluated in samples of T1D donors by immunofluorescence. Cytokine-induced PDL1 expression in the human beta cell line, EndoC-βH1, and in primary human pancreatic islets was determined by real-time RT-PCR, flow cytometry and Western blot. Specific and previously validated small interference RNAs were used to inhibit STAT1, STAT2, IRF1 and JAK1 signaling. Key results were validated using the JAK inhibitor Ruxolitinib.

Findings: PDL1 was present in insulin-positive cells from twelve T1D individuals (6 living and 6 deceased donors) but absent from insulin-deficient islets or from the islets of six non-diabetic controls. Interferons-α and -γ, but not interleukin-1β, induced PDL1 expression in vitro in human islet cells and EndoC-βH1 cells. Silencing of STAT1 or STAT2 individually did not prevent interferon-α-induced PDL1, while blocking of JAKs - a proposed therapeutic strategy for T1D - or IRF1 prevented PDL1 induction.

Interpretation: These findings indicate that PDL1 is expressed in beta cells from people with T1D, possibly to attenuate the autoimmune assault, and that it is induced by both type I and II interferons via IRF1.

Citing Articles

Beta cell dysfunction occurs independently of insulitis in type 1 diabetes pathogenesis.

Huber M, Widener A, Cuaycal A, Smurlick D, Butterworth E, Lenchik N bioRxiv. 2025; .

PMID: 39763971 PMC: 11703223. DOI: 10.1101/2024.12.29.630665.

Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association.

Kamitani F, Nishioka Y, Koizumi M, Nakajima H, Kurematsu Y, Okada S J Diabetes Investig. 2024; 16(2):334-342.

PMID: 39569589 PMC: 11786175. DOI: 10.1111/jdi.14362.

Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8 T cell activity and biomarker during the evolution of type 1 diabetes.

Rao C, Cater D, Roy S, Xu J, De Oliveira A, Evans-Molina C Diabetologia. 2024; 68(2):382-396.

PMID: 39508879 DOI: 10.1007/s00125-024-06313-2.

Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future.

Mallone R, Sims E, Achenbach P, Mathieu C, Pugliese A, Atkinson M Diabetes. 2024; 74(1):12-21.

PMID: 39446565 PMC: 11664023. DOI: 10.2337/db24-0439.

Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes.

Rao C, Cater D, Roy S, Xu J, Olivera A, Evans-Molina C bioRxiv. 2024; .

PMID: 39345410 PMC: 11429676. DOI: 10.1101/2024.09.18.613649.

References

Loke P, Allison J . PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003; 100(9):5336-41. PMC: 154346. DOI: 10.1073/pnas.0931259100. View

Ansari M, Salama A, Chitnis T, Smith R, Yagita H, Akiba H . The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198(1):63-9. PMC: 2196083. DOI: 10.1084/jem.20022125. View

Martin-Orozco N, Wang Y, Yagita H, Dong C . Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol. 2006; 177(12):8291-5. DOI: 10.4049/jimmunol.177.12.8291. View

Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M, Boggi U . The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia. 2007; 50(12):2486-94. DOI: 10.1007/s00125-007-0816-8. View

Eizirik D, Colli M, Ortis F . The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009; 5(4):219-26. DOI: 10.1038/nrendo.2009.21. View

Moore F, Naamane N, Colli M, Bouckenooghe T, Ortis F, Gurzov E . STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and islet inflammation. J Biol Chem. 2010; 286(2):929-41. PMC: 3020778. DOI: 10.1074/jbc.M110.162131. View

Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P . A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest. 2011; 121(9):3589-97. PMC: 3163974. DOI: 10.1172/JCI58447. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell C, Bradley J . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367(6):495-507. DOI: 10.1056/NEJMoa1109071. View

10.

Cnop M, Abdulkarim B, Bottu G, Cunha D, Igoillo-Esteve M, Masini M . RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. Diabetes. 2014; 63(6):1978-93. DOI: 10.2337/db13-1383. View

11.

Krogvold L, Edwin B, Buanes T, Ludvigsson J, Korsgren O, Hyoty H . Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014; 57(4):841-3. DOI: 10.1007/s00125-013-3155-y. View

12.

Ferreira R, Guo H, Coulson R, Smyth D, Pekalski M, Burren O . A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014; 63(7):2538-50. PMC: 4066333. DOI: 10.2337/db13-1777. View

13.

Fadista J, Vikman P, Ottosson Laakso E, Mollet I, Esguerra J, Taneera J . Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc Natl Acad Sci U S A. 2014; 111(38):13924-9. PMC: 4183326. DOI: 10.1073/pnas.1402665111. View

14.

Li R, Lee J, Kim M, Liu V, Moulik M, Li H . PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes. 2014; 64(2):529-40. PMC: 4303975. DOI: 10.2337/db13-1737. View

15.

Ohaegbulam K, Assal A, Lazar-Molnar E, Yao Y, Zang X . Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2014; 21(1):24-33. PMC: 4282825. DOI: 10.1016/j.molmed.2014.10.009. View

16.

El Khatib M, Sakuma T, Tonne J, Mohamed M, Holditch S, Lu B . β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015; 22(5):430-8. PMC: 4520544. DOI: 10.1038/gt.2015.18. View

17.

Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B . Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015; 38(4):e55-7. PMC: 4370325. DOI: 10.2337/dc14-2349. View

18.

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

19.

Marroqui L, Dos Santos R, Floyel T, Grieco F, Santin I, Op de Beeck A . TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells. Diabetes. 2015; 64(11):3808-17. DOI: 10.2337/db15-0362. View

20.

Op de Beeck A, Eizirik D . Viral infections in type 1 diabetes mellitus--why the β cells?. Nat Rev Endocrinol. 2016; 12(5):263-273. PMC: 5348720. DOI: 10.1038/nrendo.2016.30. View